clinical trial · NCT05469113
A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants
Eli Lilly and Company·phase1·completed·n = 16
HealthyRepaglinideSelpercatinib
brief summary
The main purpose of this study is to assess the effect of selpercatinib on how fast repaglinide gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. Information about safety and tolerability will be collected. The study will last up to 12 days.
started
Jan 29, 2019
primary completion
Mar 5, 2019
completion
Mar 5, 2019
last updated
Dec 11, 2025
official title
An Open-Label, Fixed-Sequence Study to Evaluate the Effect of Multiple Doses of LOXO-292 on the Single Dose Pharmacokinetics of Repaglinide in Healthy Adult Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol